Table 1 Baseline clinical characteristics of included studies
Study | Year | Country | Design | Study period | Median follow-up time, months (range) | Disease status | Sample size | Median age, years (range) | Gender male/female | Primary intervention | Main outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|
de la Fuente, et al | 2019 | United States | Retrospective | 2005/2–2018/8 | 68(17–154) | Primary vitreoretinal lymphoma (PVRL) | 12 | 64(38–81) | 7/5 | Bilateral RT + MTX-based chemotherapy | CR, OR, PFS, OS, AEs |
Kaburaki, et al | 2017 | Japan | One-arm Prospective Trial | 2008/8–2015/3 | 48.9(15.3–95.1) | Primary intraocular lymphoma (PIOL) | 17 | 63(43–72) | 9/8 | ioMTX + R-MPV + rdWBRT | CR, OR, PFS, OS, AEs |
Hoang-Xuan, et al | 2020 | France | Prospective Multi-center, Open-label, Phase II trial | 2017/7–2019/10 | 6.7(0.2–27.4) | Primary CNS lymphoma (PCNSL) and PVRL | 50(9) | 72(43–83) | / | Pembrolizumab monotherapy | CR, OR, PFS, AEs |
Akiyama, et al | 2016 | Japan | Single-arm Prospective study | 2007/1–2013/12 | 29.5 | PIOL | 10 | 68.5 | 4/6 | ioMTX + systemic high-dose MTX | CR, OR, AEs |
Taoka, et al | 2012 | Japan | Retrospective | 2007/11–2009/12 | 32(21–42) | PIOL | 5 | 65(43–72) | 2/3 | ioMTX + R-MPV + rdWBRT | DFS, CR |
Soussain, et al | 2019 | France | Prospective Multi-center, Open-label, Phase II trial | 2015/9–2016/7 | 25.7(0.7–30.5) | R/R PCNSL and PVRL | 44(14) | 70(52–81) | / | Ibrutinib | CR, OR, OS, PFS, AEs |
Zhang, et al | 2022 | China | Prospective Multi-center, Open-label, Phase II trial | 2020/8–2022/1 | 12.4(0.3–18.1) | PVRL | 10 | 55(39–70) | 3/7 | Btki + ioMTX | PFS, AEs |
Guan, et al | 2022 | China | Prospective Single-center, Open-label, Phase II trial | 2020/10–2022/4 | 8.3(2.5–21.4) | Vitreoretinal lymphoma (VRL) | 10 | / | / | Ibrutinib zanubrutinib orelabrutinib | CR, OR, PFS, OS |
Zhang, et al | 2021 | China | Prospective Single-center, Open-label, Phase II trial | 2018/8–2020/1 | 18.3(10.6–27.8) | PVRL | 11 | 58(48–70) | 3/8 | R2 + ioMTX Lenalidomide maintain | CR, OR, PFS, OS |
Baron, et al | 2020 | France | Retrospective | / | 42(9–115) | PVRL | 21 | 75(35–90) | / | Temozolomide | CR, OR, PFS, OS |
Zhou, et al | 2022 | China | Retrospective | 2009/4–2019/8 | 30.55(12–73) | VRL | 40 | 62.5(31–81) | 14/26 | ioMTX + MTX-based chemotherapy | mPFS, OS |
Anthony, et al | 2021 | United States | Retrospective | / | 26(3–49) | PVRL | 7 | 69(56–85) | 4/3 | ioMTX ± systemic chemotherapy | CR, OR, PFS |
Hsu, et al | 2022 | China | Retrospective | 2013/1–2018/1 | / | Intraocular lymphoma (IOL) | 12 | / | 5/7 | ioMTX + systemic high-dose MTX | CR, OR, OS, PFS, AEs |
Ma, et al | 2016 | China | Retrospective | 2003/1–2013/12 | 40.2(4.4–123.3) | PIOL | 19 | 57(39–77) | 6/13 | ioMTX + systemic high-dose MTX | CR, OR, OS, mPFS, AEs |
Lam, et al | 2021 | French | Retrospective | 2011/1–2018/3 | 61(50–71) | PVRL | 59 | 70(39–88) | 14/45 | IV HD-MTX based systemic therapy | CR, OR, mPFS, OS, AEs |
Wang, et al | 2021 | China | Retrospective | 2020/5-? | 7.5(4–15) | VRL | 11 | 61(41–73) | 4/7 | zanubrutinib orelabrutin | CR, OR, PFS, AEs |
Cheah, et al | 2016 | United States | Retrospective database | 2007/10–2015/4 | 50.4(21.6–91.2) | Primary intraocular lymphoma (PIOL) | 11 | 66(48–72) | 2/9 | Bilateral RT + MTX-based chemotherapy | CR, OR, AEs, mPFS, OS |
Klimova, et al | 2018 | Czech Republic | Retrospective | 2004–2016 | 56(3–166) | PVRL and PCNSL | 20 (10) | 20 (10) | / | multiple combination therapies | 5OS, PFS, OS |
Castellino, et al | 2019 | United States | Retrospective | 1990–2018 | 33.6(1.2–175.2) | primary and concurrent VRL | 69 | 65(36–85) | 34/35 | multiple combination therapies | mFFS, CNS-RFS,OS |
Gozzi, et al | 2021 | Italy | Retrospective | 2006/1–2020/10 | 22(9–58) | VRL | 22 | 65(55–72) | 10/12 | multiple combination therapies | 5OS, PFS |
Kim, et al | 2016 | United States | Retrospective | 1994–2010 | 29(10.2–96.4) | primary and concurrent IOL | 22 | 65 | 8/14 | multiple combination therapies | FFS, OS |
Riemens, et al | 2015 | Europe | Retrospective | 1991/1–2012/12 | 49(15–246) | primary vitreoretinal lymphoma (PVRL) | 78 | 58(38–86) | 34/44 | multiple combination therapies | OS, PFS |
Lee, et al | 2015 | Korea | Retrospective | 2007/12–2014/6 | / | IOL | 20 | 59(34–76) | 13/7 | multiple combination therapies | mPFS, OS |
Teckie, et al | 2014 | United States | Retrospective | 1999–2011 | 25(2–150) | primary intraocular lymphoma (PIOL) | 18 | 64(32–82) | 7/11 | multiple combination therapies | ORR, 2OS, 2PFS |